REFERENCES
1. Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542-56.
3. Arab JP, Díaz LA, Rehm J, et al. Metabolic dysfunction and alcohol-related liver disease (MetALD): position statement by an expert panel on alcohol-related liver disease. J Hepatol. 2025;82:744-56.
4. Harrison SA, Bedossa P, Guy CD, et al; MAESTRO-NASH Investigators. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390:497-509.
5. Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492-542.
6. Leggio L, Hendershot CS, Farokhnia M, et al. GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders. Nat Med. 2023;29:2993-5.
7. Manthey J, Shield KD, Rylett M, Hasan OSM, Probst C, Rehm J. Global alcohol exposure between 1990 and 2017 and forecasts until 2030: a modelling study. Lancet. 2019;393:2493-502.
8. Yun B, Park H, Ahn SH, Oh J, Kim BK, Yoon JH. Liver cancer risk across metabolic dysfunction-associated steatotic liver disease and/or alcohol: a nationwide study. Am J Gastroenterol. 2025;120:410-9.
9. Younossi ZM, de Avila L, Racila A, et al. Prevalence and predictors of cirrhosis and portal hypertension in the United States. Hepatology. 2025;Epub ahead of print.
10. John BV, Bastaich D, Mezzacappa C, et al; Veterans Analysis of Liver Disease (VALID) group of investigators. Identifying metabolic dysfunction-associated steatotic liver disease using natural language processing in a US national cohort. Am J Gastroenterol. 2025; Epub ahead of print.
11. Oh R, Kim S, Cho SH, et al. Metabolic dysfunction-associated steatotic liver disease and all-cause and cause-specific mortality. Diabetes Metab J. 2025;49:80-91.
12. Shine BK, Son M, Moon SY, Han SH. Metabolic dysfunction-associated steatotic liver disease and the risk of chronic periodontitis: a nationwide cohort study. Nutrients. 2024;17:125.
13. Baek SU, Yoon JH. High-sensitivity C-reactive protein levels in metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic alcohol-associated liver disease (MetALD), and alcoholic liver disease (ALD) with metabolic dysfunction. Biomolecules. 2024;14:1468.
14. Oh R, Kim G, Lee KN, et al. Metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: risk of heart failure. Cardiovasc Diabetol. 2024;23:391.
15. Díaz LA, Lazarus JV, Fuentes-López E, et al. Disparities in steatosis prevalence in the United States by race or ethnicity according to the 2023 criteria. Commun Med. 2024;4:219.
16. Shi GX, Qian YS, Jiang CM, et al. Prevalence of steatotic liver disease (MASLD, MetALD, ALD) and clinically significant fibrosis in US adolescents: Authors’ name. Sci Rep. 2024;14:25724.
17. Ogawa Y, Tomeno W, Imamura Y, et al. Distribution of Fibrosis-4 index and vibration-controlled transient elastography-derived liver stiffness measurement for patients with metabolic dysfunction-associated steatotic liver disease in health check-up. Hepatol Res. 2024;Epub ahead of print.
18. Park HJ, Lee S, Lee JS. Differences in the prevalence of NAFLD, MAFLD, and MASLD according to changes in the nomenclature in a health check-up using MRI-derived proton density fat fraction. Abdom Radiol. 2024;49:3036-44.
19. Mori K, Tanaka M, Sato T, et al. Metabolic dysfunction-associated steatotic liver disease (SLD) and alcohol-associated liver disease, but not SLD without metabolic dysfunction, are independently associated with new onset of chronic kidney disease during a 10-year follow-up period. Hepatol Res. 2024;Epub ahead of print.
20. Kim GA, Jeong S, Jang H, Lee DH, Joo SK, Kim W. Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatotic liver disease with increased alcohol intake increase the risk of developing hepatocellular carcinoma and incident or decompensated cirrhosis: a Korean nationwide study. Liver Cancer. 2024;13:426-37.
21. Lee CM, Yoon EL, Kim M, et al. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings. Hepatology. 2024;79:1393-400.
22. Schneider CV, Schneider KM, Raptis A, Huang H, Trautwein C, Loomba R. Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population. Aliment Pharmacol Ther. 2024;59:1271-81.
23. Choe HJ, Moon JH, Kim W, Koo BK, Cho NH. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: a community-dwelling cohort study with 20-year follow-up. Metabolism. 2024;153:155800.
24. Gawrieh S, Vilar-Gomez E, Woreta TA, et al. Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States. Aliment Pharmacol Ther. 2024;59:666-79.
25. Miwa T, Tajirika S, Imamura N, et al. Prevalence of steatotic liver disease based on a new nomenclature in the japanese population: a health checkup-based cross-sectional study. J Clin Med. 2024;13:1158.
26. Israelsen M, Torp N, Johansen S, et al; GALAXY consortium. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study. Lancet Gastroenterol Hepatol. 2024;9:218-28.
27. Ciardullo S, Carbone M, Invernizzi P, Perseghin G. Exploring the landscape of steatotic liver disease in the general US population. Liver Int. 2023;43:2425-33.
28. Yang AH, Tincopa MA, Tavaglione F, et al. Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA. Gut. 2024;73:2045-53.
29. Sogabe M, Okahisa T, Kagawa M, et al. The association between alcohol consumption and cardiometabolic factors and liver fibrosis in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated liver disease. Aliment Pharmacol Ther. 2024;60:1587-98.
30. Wegermann K, Garrett ME, Zheng J, et al. Sex and menopause modify the effect of single nucleotide polymorphism genotypes on fibrosis in NAFLD. Hepatol Commun. 2021;5:598-607.
31. Paik JM, Golabi P, Biswas R, Alqahtani S, Venkatesan C, Younossi ZM. Nonalcoholic fatty liver disease and alcoholic liver disease are major drivers of liver mortality in the United States. Hepatol Commun. 2020;4:890-903.
32. Uluk D, Pein J, Herda S, et al. Metabolic dysfunction-associated steatotic liver disease (MASLD) impacts long-term outcomes after curative-intent surgery for hepatocellular carcinoma. Aliment Pharmacol Ther. 2025;61:1318-32.
33. Tamaki N, Kimura T, Wakabayashi SI, et al. Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality. Aliment Pharmacol Ther. 2024;60:61-9.
34. Joo K, Kang YW, Moon SY, Baek YH, Son M. Association between nonalcoholic fatty liver disease scores and chronic periodontitis: a retrospective cohort study. J Periodontol. 2025;96:490-8.
35. Blasco-Baque V, Garidou L, Pomié C, et al. Periodontitis induced by porphyromonas gingivalis drives periodontal microbiota dysbiosis and insulin resistance via an impaired adaptive immune response. Gut. 2017;66:872-85.
36. Khan S, Barrington G, Bettiol S, Barnett T, Crocombe L. Is overweight/obesity a risk factor for periodontitis in young adults and adolescents? Obes Rev. 2018;19:852-83.
37. Ahmad A, Furuta M, Shinagawa T, et al. Association of periodontal status with liver abnormalities and metabolic syndrome. J Oral Sci. 2015;57:335-43.
38. Akinkugbe AA, Avery CL, Barritt AS, et al. Do genetic markers of inflammation modify the relationship between periodontitis and nonalcoholic fatty liver disease? J Dent Res. 2017;96:1392-9.
39. Kimura T, Tamaki N, Wakabayashi SI, et al. Colorectal cancer incidence in steatotic liver disease (MASLD, MetALD, and ALD). Clin Gastroenterol Hepatol. 2025;Epub ahead of print.
40. Targher G, Byrne CD. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nat Rev Nephrol. 2017;13:297-310.
41. Lake JE, Overton T, Naggie S, et al. Expert panel review on nonalcoholic fatty liver disease in persons with human immunodeficiency virus. Clin Gastroenterol Hepatol. 2022;20:256-68.
42. Gawrieh S, Lake JE, Debroy P, et al. Burden of fatty liver and hepatic fibrosis in persons with HIV: a diverse cross-sectional US multicenter study. Hepatology. 2023;78:578-91.
43. Bao X, Kang L, Yin S, et al. Association of MAFLD and MASLD with all-cause and cause-specific dementia: a prospective cohort study. Alzheimers Res Ther. 2024;16:136.
44. Cheon SY, Song J. Novel insights into non-alcoholic fatty liver disease and dementia: insulin resistance, hyperammonemia, gut dysbiosis, vascular impairment, and inflammation. Cell Biosci. 2022;12:99.
45. de la Monte SM. Insulin resistance and neurodegeneration: progress towards the development of new therapeutics for Alzheimer’s disease. Drugs. 2017;77:47-65.
46. Shin WY, Kang ES, Oh YH, et al. Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study: MASLD, MetALD, and dementia risk. BMC Gastroenterol. 2025;25:308.
47. Li Y, Chao X, Wang S, Williams JA, Ni HM, Ding WX. Role of mechanistic target of rapamycin and autophagy in alcohol-induced adipose atrophy and liver injury. Am J Pathol. 2020;190:158-75.
48. Li W, Zhu X, Song Y, et al. Intakes of magnesium, calcium and risk of fatty liver disease and prediabetes. Public Health Nutr. 2018;21:2088-95.
49. Barbagallo M, Veronese N, Dominguez LJ. Magnesium in type 2 diabetes mellitus, obesity, and metabolic syndrome. Nutrients. 2022;14:714.
50. Jokinen MJ, Luukkonen PK. Hepatic mitochondrial reductive stress in the pathogenesis and treatment of steatotic liver disease. Trends Pharmacol Sci. 2024;45:319-34.
51. Jew MH, Hsu CL. Alcohol, the gut microbiome, and liver disease. J Gastroenterol Hepatol. 2023;38:1205-10.
52. Raya Tonetti F, Eguileor A, Mrdjen M, et al. Gut-liver axis: recent concepts in pathophysiology in alcohol-associated liver disease. Hepatology. 2024;80:1342-71.
53. Romeo S, Sanyal A, Valenti L. Leveraging human genetics to identify potential new treatments for fatty liver disease. Cell Metab. 2020;31:35-45.
54. Duan H, Gong M, Yuan G, Wang Z. Sex hormone: a potential target at treating female metabolic dysfunction-associated steatotic liver disease? J Clin Exp Hepatol. 2025;15:102459.
55. Åberg F, Byrne CD, Pirola CJ, Männistö V, Sookoian S. Alcohol consumption and metabolic syndrome: clinical and epidemiological impact on liver disease. J Hepatol. 2023;78:191-206.
56. Traversy G, Chaput JP. Alcohol consumption and obesity: an update. Curr Obes Rep. 2015;4:122-30.
57. Zhai X, Li S, Wang T, Bai J, Xu F, Zhou W. Dark tea wine protects against metabolic dysfunction-associated steatotic liver disease in vivo through activating the Nrf2/HO-1 antioxidant signaling pathway. J Med Food. 2024;27:912-21.
58. Cecchini M, Filippini T, Whelton PK, et al. Alcohol intake and risk of hypertension: a systematic review and dose-response meta-analysis of nonexperimental cohort studies. Hypertension. 2024;81:1701-15.
59. Puddey IB, Beilin LJ, Vandongen R. Regular alcohol use raises blood pressure in treated hypertensive subjects. A randomised controlled trial. Lancet. 1987;1:647-51.
60. Masengere P, Halbesma N, Ndejjo R, et al. Additive interaction of conjoint tobacco smoking and heavy drinking on hypertension prevalence in rural Uganda: a community-based cross-sectional study. BMC Public Health. 2025;25:201.
61. Mukhopadhyay P, Yokus B, Paes-Leme B, et al. Chronic alcohol consumption accelerates cardiovascular aging and decreases cardiovascular reserve capacity. Geroscience. 2025;Epub ahead of print.
62. Llamosas-Falcón L, Rehm J, Bright S, et al. The relationship between alcohol consumption, BMI, and type 2 diabetes: a systematic review and dose-response meta-analysis. Diabetes Care. 2023;46:2076-83.
63. Baliunas DO, Taylor BJ, Irving H, et al. Alcohol as a risk factor for type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2009;32:2123-32.
64. Schrieks IC, Heil AL, Hendriks HF, Mukamal KJ, Beulens JW. The effect of alcohol consumption on insulin sensitivity and glycemic status: a systematic review and meta-analysis of intervention studies. Diabetes Care. 2015;38:723-32.
65. Kim JY, Song EH, Lee HJ, et al. Chronic ethanol consumption-induced pancreatic β-cell dysfunction and apoptosis through glucokinase nitration and its down-regulation. J Biol Chem. 2010;285:37251-62.
66. Rasineni K, Srinivasan MP, Balamurugan AN, et al. Recent advances in understanding the complexity of alcohol-induced pancreatic dysfunction and pancreatitis development. Biomolecules. 2020;10:669.
67. Fu Q, Dai H, Shen S, et al. Interactions of genes with alcohol consumption affect insulin sensitivity and beta cell function. Diabetologia. 2025;68:116-27.
68. Brien SE, Ronksley PE, Turner BJ, Mukamal KJ, Ghali WA. Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: systematic review and meta-analysis of interventional studies. BMJ. 2011;342:d636.
69. Thiele M, Suvitaival T, Trošt K, et al; MicrobLiver Consortium, GALAXY Consortium. Sphingolipids are depleted in alcohol-related liver fibrosis. Gastroenterology. 2023;164:1248-60.
71. Gluchowski NL, Becuwe M, Walther TC, Farese RV Jr. Lipid droplets and liver disease: from basic biology to clinical implications. Nat Rev Gastroenterol Hepatol. 2017;14:343-55.
72. Williams JA, Ding WX. A mechanistic review of mitophagy and its role in protection against alcoholic liver disease. Biomolecules. 2015;5:2619-42.
73. Wu H, Cai P, Clemens DL, Jerrells TR, Ansari GA, Kaphalia BS. Metabolic basis of ethanol-induced cytotoxicity in recombinant HepG2 cells: role of nonoxidative metabolism. Toxicol Appl Pharmacol. 2006;216:238-47.
75. Turecky L, Kupcova V, Szantova M, Uhlikova E, Viktorinova A, Czirfusz A. Serum magnesium levels in patients with alcoholic and non-alcoholic fatty liver. Bratisl Lek Listy. 2006;107:58-61.
76. Gommers LM, Hoenderop JG, Bindels RJ, de Baaij JH. Hypomagnesemia in type 2 diabetes: a vicious circle? Diabetes. 2016;65:3-13.
77. Fan L, Zhu X, Zhang X, et al. Magnesium depletion score and mortality in individuals with metabolic dysfunction associated steatotic liver disease over a median follow-up of 26 years. Nutrients. 2025;17:244.
78. Zakhari S. Overview: how is alcohol metabolized by the body? Alcohol Res Health. 2006;29:245-54.
80. Crabb DW, Matsumoto M, Chang D, You M. Overview of the role of alcohol dehydrogenase and aldehyde dehydrogenase and their variants in the genesis of alcohol-related pathology. Proc Nutr Soc. 2004;63:49-63.
81. Cederbaum AI, Lu Y, Wu D. Role of oxidative stress in alcohol-induced liver injury. Arch Toxicol. 2009;83:519-48.
83. McGarry JD, Foster DW. Regulation of hepatic fatty acid oxidation and ketone body production. Annu Rev Biochem. 1980;49:395-420.
84. Ding Z, Ericksen RE, Escande-Beillard N, et al. Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis. J Hepatol. 2020;72:725-35.
85. Luukkonen PK, Dufour S, Lyu K, et al. Effect of a ketogenic diet on hepatic steatosis and hepatic mitochondrial metabolism in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A. 2020;117:7347-54.
86. Yuan J, Chen C, Cui J, et al. Fatty liver disease caused by high-alcohol-producing klebsiella pneumoniae. Cell Metab. 2019;30:675-88.e7.
87. Luukkonen PK, Porthan K, Ahlholm N, et al. The PNPLA3 I148M variant increases ketogenesis and decreases hepatic de novo lipogenesis and mitochondrial function in humans. Cell Metab. 2023;35:1887-96.e5.
88. Jamialahmadi O, Mancina RM, Ciociola E, et al. Exome-wide association study on alanine aminotransferase identifies sequence variants in the GPAM and APOE associated with fatty liver disease. Gastroenterology. 2021;160:1634-46.e7.
89. Liu YL, Reeves HL, Burt AD, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun. 2014;5:4309.
90. Buch S, Stickel F, Trépo E, et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat Genet. 2015;47:1443-8.
91. Nataraj K, Schonfeld M, Rodriguez A, Sharma M, Weinman S, Tikhanovich I. Androgen effects on alcohol-induced liver fibrosis are controlled by a notch-dependent epigenetic switch. Cell Mol Gastroenterol Hepatol. 2025;19:101414.
92. Teng ML, Ng CH, Huang DQ, et al. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023;29:S32-42.
93. Danpanichkul P, Díaz LA, Suparan K, et al. Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000-2021. Clin Mol Hepatol. 2025;31:525-47.
94. Danpanichkul P, Pang Y, Mahendru T, et al. Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States. Clin Mol Hepatol. 2025;31:1058-70.
95. Nataraj K, Schonfeld M, Rodriguez A, Tikhanovich I. Protective role of 17β-estradiol in alcohol-associated liver fibrosis is mediated by suppression of integrin signaling. Hepatol Commun. 2024;8:e0428.
96. Malnick SDH, Alin P, Somin M, Neuman MG. Fatty liver disease-alcoholic and non-alcoholic: similar but different. Int J Mol Sci. 2022;23:16226.
97. Yip TC, Lee HW, Lin H, et al. Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease. J Hepatol. 2025;83:304-14.
98. Wattacheril JJ, Abdelmalek MF, Lim JK, Sanyal AJ. AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review. Gastroenterology. 2023;165:1080-8.
99. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797-835.
100. Díaz LA, Tavaglione F, Mittal N, et al. Noninvasive pathway for stratifying fibrosis in suspected metabolic dysfunction and alcohol-associated liver disease (MetALD). Hepatol Commun. 2025;9:e0718.
101. Oh JH, Ahn SB, Cho S, Nah EH, Yoon EL, Jun DW. Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort. J Hepatol. 2024;81:772-80.
102. Morinaga M, Kon K, Uchiyama A, et al. Carbohydrate-deficient transferrin is a sensitive marker of alcohol consumption in fatty liver disease. Hepatol Int. 2022;16:348-58.
103. Nguyen VL, Paull P, Haber PS, Chitty K, Seth D. Evaluation of a novel method for the analysis of alcohol biomarkers: ethyl glucuronide, ethyl sulfate and phosphatidylethanol. Alcohol. 2018;67:7-13.
104. Tavaglione F, Amangurbanova M, Yang AH, et al. Head-to-head comparison between phosphatidylethanol versus indirect alcohol biomarkers for diagnosis of MetALD versus MASLD: a prospective study. Aliment Pharmacol Ther. 2025;61:1043-54.
105. Staufer K, Huber-Schönauer U, Strebinger G, et al. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease. J Hepatol. 2022;77:918-30.
106. Arab JP, Izzy M, Leggio L, Bataller R, Shah VH. Management of alcohol use disorder in patients with cirrhosis in the setting of liver transplantation. Nat Rev Gastroenterol Hepatol. 2022;19:45-59.
107. Finanger T, Melby K, Spigset O, Andreassen TN, Lydersen S, Skråstad RB. Relationship between alcohol intake based on daily smartphone-reported consumption and PEth concentrations in healthy volunteers. Alcohol Alcohol. 2024;59:agae040.
108. Aradottir S, Asanovska G, Gjerss S, Hansson P, Alling C. PHosphatidylethanol (PEth) concentrations in blood are correlated to reported alcohol intake in alcohol-dependent patients. Alcohol Alcohol. 2006;41:431-7.
109. Viel G, Boscolo-Berto R, Cecchetto G, Fais P, Nalesso A, Ferrara SD. Phosphatidylethanol in blood as a marker of chronic alcohol use: a systematic review and meta-analysis. Int J Mol Sci. 2012;13:14788-812.
110. Grant BF, Chou SP, Saha TD, et al. Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States, 2001-2002 to 2012-2013: results from the national epidemiologic survey on alcohol and related conditions. JAMA Psychiatry. 2017;74:911-23.
111. Piano MR, Tiwari S, Nevoral L, Phillips SA. Phosphatidylethanol levels are elevated and correlate strongly with AUDIT scores in young adult binge drinkers. Alcohol Alcohol. 2015;50:519-25.
112. Tavaglione F, Díaz LA, Ajmera V, et al. Clinical utility of phosphatidylethanol to detect underreported alcohol use and enhance steatotic liver disease subclassification. J Hepatol. 2025;Epub ahead of print.
113. Díaz LA, Collier S, Yin J, Loomba R. Safety and tolerability of injectable extended-release naltrexone for the management of alcohol use disorder in advanced alcohol-associated liver disease. Aliment Pharmacol Ther. 2025:Epub ahead of print.
114. Vannier AGL, Shay JES, Fomin V, et al. Incidence and progression of alcohol-associated liver disease after medical therapy for alcohol use disorder. JAMA Netw Open. 2022;5:e2213014.
116. Harrison SA, Bashir MR, Guy CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019;394:2012-24.
117. Delerive P, De Bosscher K, Besnard S, et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem. 1999;274:32048-54.
118. Sugimoto R, Iwasa M, Eguchi A, et al. Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients. Front Med. 2023;10:1073025.
119. Yu S, Rao S, Reddy JK. Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. Curr Mol Med. 2003;3:561-72.
120. Iwasa M, Sugimoto R, Eguchi A, et al. Effectiveness of 1-year pemafibrate treatment on steatotic liver disease: the influence of alcohol consumption. Eur J Gastroenterol Hepatol. 2024;36:793-801.
121. Cariou B, Zaïr Y, Staels B, Bruckert E. Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care. 2011;34:2008-14.
122. Koizumi A, Kaji K, Nishimura N, et al. Effects of elafibranor on liver fibrosis and gut barrier function in a mouse model of alcohol-associated liver disease. World J Gastroenterol. 2024;30:3428-46.
123. Ratziu V, Harrison SA, Francque S, et al; GOLDEN-505 Investigator Study Group. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 2016;150:1147-59.e5.
124. Pirola L. Elafibranor, a dual PPARα and PPARδ agonist, reduces alcohol-associated liver disease: lessons from a mouse model. World J Gastroenterol. 2025;31:99312.
125. Cheng CH, Hao WR, Cheng TH. Elafibranor: a promising therapeutic approach for liver fibrosis and gut barrier dysfunction in alcohol-associated liver disease. World J Gastroenterol. 2025;31:98783.
126. Armstrong MJ, Hull D, Guo K, et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol. 2016;64:399-408.
127. Knop FK, Aroda VR, do Vale RD, et al; OASIS 1 Investigators. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402:705-19.
128. Rubino D, Abrahamsson N, Davies M, et al; STEP 4 Investigators. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325:1414-25.
129. Newsome PN, Buchholtz K, Cusi K, et al; NN9931-4296 Investigators. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384:1113-24.
130. Armstrong MJ, Gaunt P, Aithal GP, et al; LEAN trial team. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679-90.
131. Loomba R, Abdelmalek MF, Armstrong MJ, et al; NN9931-4492 investigators. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8:511-22.
132. Newsome PN, Sanyal AJ, Engebretsen KA, et al. Semaglutide 2.4 mg in participants with metabolic dysfunction-associated steatohepatitis: baseline characteristics and design of the phase 3 ESSENCE trial. Aliment Pharmacol Ther. 2024;60:1525-33.
133. Sanyal AJ, Newsome PN, Kliers I, et al; ESSENCE Study Group. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392:2089-99.
134. Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145:574-82.e1.
135. Patel K, Harrison SA, Elkhashab M, et al. Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial. Hepatology. 2020;72:58-71.
136. Fiorucci S, Biagioli M, Baldoni M, et al. The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease. Expert Opin Drug Discov. 2021;16:1193-208.
137. Alkhouri N, Herring R, Kabler H, et al. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial. J Hepatol. 2022;77:607-18.
138. Loomba R, Noureddin M, Kowdley KV, et al; for the ATLAS Investigators. Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH. Hepatology. 2021;73:625-43.
139. Yakubu I, Spengler J, Taylor P, et al. Impact of glucagon-like peptide-1 receptor agonists on metabolic health in liver transplant recipients. Transplantation. 2025;Epub ahead of print.
140. Zhao Q, Wang X, Liu K, et al. Activation of farnesoid X receptor enhances the efficacy of normothermic machine perfusion in ameliorating liver ischemia-reperfusion injury. Am J Transplant. 2024;24:1610-22.
141. Bajaj JS, Gavis EA, Fagan A, et al. A randomized clinical trial of fecal microbiota transplant for alcohol use disorder. Hepatology. 2021;73:1688-700.
142. Pande A, Sharma S, Khillan V, et al. Fecal microbiota transplantation compared with prednisolone in severe alcoholic hepatitis patients: a randomized trial. Hepatol Int. 2023;17:249-61.
143. Derfoul A, Miyoshi AD, Freeman DE, Tuan RS. Glucosamine promotes chondrogenic phenotype in both chondrocytes and mesenchymal stem cells and inhibits MMP-13 expression and matrix degradation. Osteoarthritis Cartilage. 2007;15:646-55.
144. Li F, Zhang Z, Bai Y, et al. Glucosamine improves non-alcoholic fatty liver disease induced by high-fat and high-sugar diet through regulating intestinal barrier function, liver inflammation, and lipid metabolism. Molecules. 2023;28:6918.
145. Lai W, Zhou S, Bai Y, et al. Glucosamine attenuates alcohol-induced acute liver injury via inhibiting oxidative stress and inflammation. Curr Res Food Sci. 2024;8:100699.
146. Ryu T, Chang Y, Yoo JJ, et al. Glucosamine supplementation attenuates progression of metabolic dysfunction-associated steatotic liver disease and related comorbidities. Clin Nutr. 2025;47:119-28.
147. Dou JY, Liu SH, Guo J, et al. Dietary supplementation of pterostilbene, a major component in small berries, prevents alcohol-induced liver injury associated with lipid accumulation and inflammation. Food Funct. 2024;15:11206-19.
148. Benedé-Ubieto R, Estévez-Vázquez O, Guo F, et al. An experimental DUAL model of advanced liver damage. Hepatol Commun. 2021;5:1051-68.
